Dr Tayner Garzon holds an undergraduate degree in Marine Biology from Bogotá, Colombia. In 2003, he moved to Australia with the ambition of contributing to medical research. He first completed a Diploma of Technology at the Southbank Institute of Technology before earning his PhD in Molecular Genetics from Griffith University, where his research focused on the evolution of genetic lineages using molecular genetic markers. Dr Garzon joined the Cancer Research team at Discovery Biology in 2009, initially working on prostate cancer signalling pathways. As part of the Cancer Therapeutics initiative, he has played a key role in performing cell-based assays that provide critical insights into the cytotoxic effects of potential anti-cancer compounds. Over the years, he has contributed to a wide range of oncology research projects, including the evaluation of antimitotic agents, antibody–drug conjugates, lamin–microtubule destabilising agents, tyrosine kinase signalling inhibitors, and immunomodulatory strategies. Earlier in his career, he focused on dissecting androgen receptor activation complexes to advance the development of more effective therapeutic agents. Dr Garzon specialises in phenomic analysis, using advanced image-based profiling to optimise and prioritise drug hits, and to develop target identification assays essential for translational drug discovery. He led an innovative project exploring programmed ribosomal frameshifting as a strategy to overcome multidrug resistance in cancer with Canthera Discovery Ltd. This involves designing phenomic studies to uncover hidden patterns and mechanistic relationships that would otherwise remain undetected. Dr Garzon is currently investigating the interplay between focal adhesion dynamics and reactive oxygen species (ROS) in cancer progression. Leveraging advanced single-cell phenomic analysis and high-content imaging, his research developed a platform capable of differentiating aggressive, hormone-resistant triple-negative breast cancer (TNBC) from less invasive, hormone-sensitive models through distinct cytoskeletal and focal adhesion phenotypic signatures. His work examines how diverse ROS sources interface with focal adhesion kinase (FAK) signalling to promote metastasis and therapeutic resistance. By applying unsupervised multivariate statistical techniques to high-dimensional imaging data, the research identifies key biomarkers and cellular behaviours to inform the development of combination therapies targeting both adhesion signalling and redox pathways.